Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00201955 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Rebamipide Eye Drops to Treat Dry Eye

StatusCompleted
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment target: 740 to 762v4 Show 7 more changesShow less
    • Primary completion date: Jul 1, 2006
    • Study completion date: Jul 2006 to Jul 1, 2006
    • Start date: May 2004 to May 1, 2004
    • Interventions: Rebamipide (Drug) to Placebo (Drug), Rebamipide 1% (Drug), Rebamipide 2% (Drug)
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site details revised at 1 of 60 sites
    • Study arms: 0 to 3
  2. Trial status: Recruiting to Completed
    • Study sites: 61 to 60
    v3
  3. Study sites: 2 to 61v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine the potential safety and effectiveness of rebamipide eye drops, an investigational eye drop being developed for the treatment of keratoconjunctivitis sicca (dry eye).
Trial Details
NCT Number NCT00201955
Lead Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborators: Novartis
Conditions
(from sponsor)		 Keratoconjunctivitis Sicca
Related terms Dry Eye Syndromes, Keratoconjunctivitis Sicca
Enrollment 762 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov